Blow for sufferers as experimental Alzheimer's drug is scrapped
Wednesday 08 August 2012
Studies of one of the most anticipated experimental drugs for Alzheimer's disease have been scrapped after it failed to help patients with the condition in a high-profile clinical trial.
Pfizer Inc and Johnson & Johnson said they would discontinue all other studies of the drug bapineuzumab including two more trials and follow-up extension studies, in patients with mild-to-moderate Alzheimer's.
The result marked the second such late-stage failure announced in recent weeks and was especially disappointing as bapineuzumab had been given a better chance of success in the patients studied in the second trial. If successful, it would have been the first drug to fight the progression of the debilitating brain disease.
Attention will now turn to solanezumab, a similar drug being developed by Eli Lilly & Co that is also considered a long-shot to succeed, but will still carry fading hopes at least until test results are released later this year. Shares in all three drugs firms fell following news of the latest disappointment.
Any successful Alzheimer's treatment is likely to reap many billions of pounds in sales, and industry analysts said many investors were holding shares in the companies in case the drugs were to succeed. "We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer's disease," said Steven Romano, head of Pfizer's medicines development group.
Life & Style blogs
Max power: Nine ways to make your everyday meals more flavourful
Amputee drummer gains 'superhuman' skills with robotic arm
Livr: A social network only for drunk people
Fenwicks department store withdraws Boy London clothing over 'Nazi' eagle logo complaints
International Women's Day 2014: Animated Google Doodle shows 80 second video of inspirational women from across the world
- 1 To those who can’t see the point of International Women’s Day: you are the very reason it exists
- 2 International Women's Day 2014: The shocking statistics that show why it is still so important
- 3 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 4 Too upsetting? Academy members voted for Oscar-winning 12 Years A Slave 'without watching it'
- 5 Liam Neeson turned down James Bond role because Natasha Richardson said she wouldn't marry him if he took it
£12000 per annum: Inspiring Interns: A small but growing chain of boutique hot...
£12000 per annum: Inspiring Interns: The company works with Tier 1 FTSE 100 Ba...
£45 - 60k Per Annum: Charter Selection: Highly profitable leisure brand, marke...
£30000 - £50000 per annum + Highly Competitive Salary: Austen Lloyd: Residenti...